PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

• Manuel Sánchez Cánovas ^[1] ; Javier López Robles ^[1] ; Francisco José García Verdejo ^[1] ; Diego Cacho Lavin ^[1] ; Helena Olivares ^[1] ; Alberto Garrido Fernández ^[1] ; Eva Coma Salvans ^[1] ; Teresa Quintanar Verduguez ^[1] ; Carmen Salvador Coloma ^[1] ; David Fernández Garay ^[1] ; José David Cumplido ^[1] ; Ana Isabel Ferrer Pérez ^[1] ; Anna Carbó Bagué ^[1] ; Francisco Javier Teigell Muñoz ^[1] ; Ruben García López ^[2] ; Andrea Martínez Marín ^[3] ; Andrés J. Muñoz Martín
  1. [1] Spanish Society of Medical Oncology (SEOM) Thrombosis and Cancer Group, Madrid, Spain
  2. [2] Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain
  3. [3] Medical Oncology Nursing, Hospital Universitario Morales Meseguer, Murcia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 28, Nº. 3, 2026, págs. 934-941
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose: To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/ AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP).

    Methods/patients: A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT. Secondary outcomes included predictive factors for thrombosis and the impact of thrombosis on overall survival (OS). Data were analyzed using logistic regression and Kaplan–Meier survival analysis.

    Results: The incidence of VTE/AT was 4.9% (16/329). BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%; p<0.001). Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095–0.724; p=0.010). No statistically significant differences were observed in the median OS between patients who experienced VTE/ATE (63 months) and those who did not (47 months), with a p value of 0.876.

    Conclusions: BRCA2 mutations could be a significant predictor for VTE/AT among ovarian cancer patients treated with iPARP. Concomitant treatment with bevacizumab may offer protection against thrombotic events, although a concomitant bias cannot be ruled out. These findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.